Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Debt-to-Equity : 0.54 (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Debt-to-Equity?

Swedish Orphan Biovitrum AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $734 Mil. Swedish Orphan Biovitrum AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1,112 Mil. Swedish Orphan Biovitrum AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $3,447 Mil. Swedish Orphan Biovitrum AB's debt to equity for the quarter that ended in Mar. 2024 was 0.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Debt-to-Equity or its related term are showing as below:

BIOVF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.52 Max: 0.98
Current: 0.61

During the past 13 years, the highest Debt-to-Equity Ratio of Swedish Orphan Biovitrum AB was 0.98. The lowest was 0.00. And the median was 0.52.

BIOVF's Debt-to-Equity is ranked worse than
72.78% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs BIOVF: 0.61

Swedish Orphan Biovitrum AB Debt-to-Equity Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Debt-to-Equity Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.98

0.72

0.47

0.34

0.61

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.33	0.99	0.61	0.61	0.54

Competitive Comparison of Swedish Orphan Biovitrum AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Debt-to-Equity falls into.

Swedish Orphan Biovitrum AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Swedish Orphan Biovitrum AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(873.596	+	1123.46)	/	3301.65
	=	0.60

Swedish Orphan Biovitrum AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(734.298	+	1111.773)	/	3446.928
	=	0.54

Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Swedish Orphan Biovitrum AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:BIOVF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SWOBY:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).